Vance on ACA, diagnosing myopia, and fallout from a retracted study
In a story today from STAT’s Anil Oza, I learned that researcher and physician Alex…
Category: HIV/AIDS
Opinion: Tested in Africa, used in America
At the recent annual International AIDS Conference, a startling presentation about the newest wonder drug…
STAT+: Gilead’s twice-yearly antiviral protects against HIV infection in second large trial
Gilead said Thursday that its twice-yearly antiviral reduced the risk of HIV infections by 96%…
Opinion: Gilead must be held accountable for the harm caused by ‘patent hopping’ an HIV treatment
Gilead Sciences, a pharma company that dominates the market for HIV treatments, agreed in June…
Morning Rounds: Grindr gets into health care lobbying
Want to stay on top of health news? Sign up to get our Morning Rounds newsletter in…
There’s more data for trans people with HIV than any other disease — but it’s still flawed
Transgender people are at higher-than-average risk of contracting HIV. And yet, when epidemiologist Diana Tordoff…
Dating app Grindr hires Tom Daschle’s firm to lobby on HIV prevention, IVF
WASHINGTON — LGBTQ+ dating app Grindr is tapping into the Washington lobbying world amid legislative…
STAT+: A pricey Gilead HIV drug could be made for dramatically less than the company claims, researchers say
Following the release of widely touted study results for a Gilead Sciences HIV treatment, a…
Opinion: Listen: Anthony Fauci on presidents, bird flu, and turning down a multimillion-dollar job
Anthony Fauci can’t pinpoint the most meaningful dinner he’s ever had — every time you…
‘Visionary’ study finds inflammation, evidence of Covid virus years after infection
Remember when we thought Covid was a two-week illness? So does Michael Peluso, assistant professor…
STAT+: Drug wholesaler owners indicted for alleged role in diverting Gilead and J&J HIV medicines
The owners of a drug wholesaler have been indicted for their alleged role in a…
Can JAK inhibitors bolster checkpoint inhibitors?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Gilead’s twice-yearly antiviral protected women from HIV infection in large trial
Gilead said Thursday that twice-a-year injections of a new antiviral drug, called lenacapavir, completely protected…
Inside Anthony Fauci’s ‘On Call’: 9 health and science takeaways from the memoir of America’s most famous doctor
Anthony Fauci spent 40 years in the top echelons of government. It was no accident….
STAT+: Gilead to pay $40 million to settle claims it delayed newer HIV treatment to boost profits
Gilead Sciences agreed in principle to pay $40 million to more than 2,600 AIDS patients…
Animal studies lend support to an innovative HIV vaccine strategy — but there’s still a long way to go
HIV has long stumped immunologists looking to develop an effective vaccine. All of the most…
STAT+: Gilead gets a boost from California court in a case over slow-walking an HIV drug
In a boost for Gilead Sciences, the California Supreme Court agreed to review a contentious…
STAT+: Colombia issues a compulsory license for an HIV medicine and ‘plants a flag for global health equity’
After months of deliberation, the Colombian government has issued a compulsory license for an HIV…
Surge in anti-gay laws in Africa imperil progress on HIV/AIDS, experts say
The International AIDS Society (IAS) and UNAIDS have spoken out against legislation passed by Ghana’s…
HIV: WHO reports “worrying” increase in resistance to key antiretroviral treatment
Resistance to the first line HIV antiretroviral drug dolutegravir is growing and exceeding levels seen…
STAT+: Colombia proceeds with plans to issue a compulsory license for an HIV medicine sold by GSK’s ViiV
The Colombian government has taken a significant step toward issuing a compulsory license for a…
Transgender women’s higher risk for HIV is influenced by discrimination, CDC finds
Transgender women, in particular those belonging to marginalized racial and ethnic groups, have disproportionately high…
Sub-Saharan Africa registers biggest declines in AIDS infections, says UNAIDS
The numbers of people infected with and dying of AIDS worldwide have fallen, but sub-Saharan…
Opinion: PEPFAR has been a lifeline in Ukraine. Now it’s under threat
In Ukraine, a little bit of good news can go a long way, and the…
Opinion: PEPFAR, one of the greatest public health inventions of our time, is at risk
In the clinic where I work, I met a patient the other day whom I…
Is there a path forward for PEPFAR?
You’re reading the web edition of D.C. Diagnosis. Sign up here to receive this newsletter in your…
Statins reduce cardiovascular risk in people living with HIV, new global study finds
A statin a day reduces the risk of heart disease in younger people living with…
Ending AIDS by 2030 is a political choice, says UN agency
AIDS can be ended by 2030, but achieving this boils down to a “political and…
Opinion: Right-wing politicians are stoking renewed moral panic about HIV
In May, just before Pride Month, the Centers for Disease Control and Prevention released news…
First pediatric study to test neutralizing antibodies against HIV shows promise
When children living with HIV are injected with neutralizing antibodies, the treatment can suppress cells…
STAT+: Gilead and Teva defeat antitrust lawsuit that claimed prices for HIV medicines were unfairly kept high
In a setback to AIDS activists, a federal court jury on Friday cleared Gilead Sciences…
A looming penicillin shortage threatens pregnant adults with syphilis and their newborns
Pfizer announced last week that it expects to run out of a key drug for…
Opinion: Listen: How to save PrEP access — and even expand it
Under the Affordable Care Act, health insurers are required to cover all costs associated with…
Opinion: How to protect PrEP coverage, no matter what happens in Braidwood v. Becerra
Since a Texas judge’s decision dropped earlier this spring, Braidwood v. Becerra has sent shudders…
HIV rates decline in U.S., data show, but disparities persist
The newest accounting of HIV incidence in the United States is a mixed bag. Overall…
PrEP research: Gilead didn’t infringe patents, ȷury rules
The drug company Gilead Sciences won on all counts in its legal battle with the…
STAT+: Gene therapy can transform life for people with hemophilia. But some patients don’t want it.
Given everything he’s been through, Bobby Wiseman says he should have been dead instead of…
FDA eases rules again for gay men seeking to donate blood
WASHINGTON (AP) — The U.S. is moving to ease restrictions on blood donations from gay…
HIV vaccine being developed by Johnson & Johnson fails clinical trial
Yet another experimental HIV vaccine has failed. The National Institute of Allergy and Infectious Diseases…
HIV: Two in three people have trouble getting PrEP, finds survey
The UK government’s ambition to end new cases of HIV infection by 2030 is under…
STAT+: Pharmalittle: FDA advisers vote down pediatric brain cancer drug; AbbVie drops out of psoriasis partnership
Good morning, and welcome to a spooky edition of Pharmalittle. It’s Jason Mast here, filling…
Opinion: Decriminalizing HIV: Scientifically proven and morally correct
One hundred thirty-four. That’s the number of countries that currently criminalize or prosecute people based…
Opinion: Stop squandering opportunities to end AIDS: be responsive to the needs of HIV prevention users
Ten years ago this month, the Food and Drug Administration approved a daily pill that…
How the hard lessons of the AIDS crisis are shaping the response to the monkeypox outbreak
As officials, researchers and activists scramble to control an emerging monkeypox outbreak, many are doing…
STAT+: By endorsing a first injectable for HIV prevention, FDA creates alternative to pills and a battle among drug makers
In a notable development, the first long-acting injectable shot for preventing HIV was approved by…
HIV: People at highest risk of infection should be offered PrEP, says NICE
People at the highest risk of being infected with HIV should be offered pre-exposure prophylaxis,…
Opinion: Losing Faith: Reflecting on 40 years of the HIV pandemic
Faith was the first child I lost to HIV. I can still see her, sitting…
Opinion: Stigma, not science, is the biggest barrier to ending the HIV epidemic
“I am really sorry to reach out like this, David, but I’m worried about my…
Despite interventions, Black and Hispanic men are contracting HIV at the same rates as 10 years ago
Despite numerous advances in the prevention of HIV, new data show that the rate of…
Scientists report finding a second person to be ‘naturally’ cured of HIV, raising hopes for future treatments
One evening in March 2020, a doctor walked out of a hospital in the Argentine…